MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE MAY 23, 2019 MEETING

DUR Board Members:	Sep 2018	Dec 2018	Mar 2019	May 2019
Lauren Bloodworth, PharmD	✓	✓		✓
Beverly Bryant, MD	✓	✓	✓	
Rhonda Dunaway, RPh	✓	✓	✓	✓
Tanya Fitts, MD	✓	✓	✓	✓
Juanice Glaze, RPh	✓	✓	✓	
Alice Messer, DNP, FNP-BC			✓	
Ray Montalvo, MD		✓	✓	
Holly Moore, PharmD	✓	✓		✓
Janet Ricks, DO	✓	✓	✓	✓
Dennis Smith, RPh	✓	✓	✓	✓
James Taylor, PharmD (Chair)	✓	✓	✓	✓
Veda Vedanarayanan, MD		✓	✓	✓
TOTAL PRESENT	**9**	**11**	**10**	**8**

Also Present:

Division of Medicaid (DOM) Staff:
Cindy Noble, PharmD, MPH, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Sue Reno, RN, Program Integrity; Vanessa Banks, RN, Program Integrity

University of Mississippi School of Pharmacy - MS-DUR Staff:
Eric Pittman, PharmD, MS-DUR Project Director

Conduent Staff:
Lew Anne Snow, RN, BSN, Pharmacy Services Sr. Analyst, Mississippi Medicaid Project

Change Healthcare Staff:
Paige Clayton, PharmD, On-Site Clinical Pharmacist; Cheryl Rogers, PharmD, Mississippi PA Pharmacist

IBM Watson Health:
Mary Sawardecker, MHA, RHIA, Analytic Consultant Sr., Mississippi Medicaid Project

Coordinated Care Organization (CCO) Staff:
Heather Odem, PharmD, Director of Pharmacy - Mississippi, UnitedHealthcare Community & State; Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Mike Todaro; PharmD, Vice President Pharmacy Operations, Magnolia Health; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare

Visitors:
Jason Swartz, Otsuka; Eric Marchant, Amgen; Susan Abbott, AMAG; Brynna Clark, MPhA; Judy Clark, Consultant; Evelyn Johnson, Capital Resources; Allison Balducci, BMS; Meg Pearson, MS State Department of Health; Chris Shannon, MS Department of Finance and Administration; Wengora Thompson, March of Dimes; Mariah Cole, Pharmacy Student; Anna Crider, Pharmacy Student.

Call to Order:
Dr. Taylor, Chair, called the meeting to order at 1:05pm and welcomed everyone.

OLD BUSINESS:
Dr. Bloodworth moved to approve the minutes from the March 2019 DUR Board Meeting, seconded by Dr. Fitts and unanimously approved by the DUR Board.

Resource Utilization Review:
Dr. Pittman presented the resource utilization report for January – March 2019. No significant trends or shifts were noted for this period.

NEW Business

Update on MS-DUR Educational Interventions:
Dr. Pittman provided an overview of all DUR mailings that occurred February – April 2019.

Special Analysis Projects:
Update on Makena Utilization in Mississippi Medicaid
Dr. Meg Pearson with the MS State Department of Health gave a historical presentation to the Board on the Department of Health's efforts to improve access to Makena in Mississippi. Dr. Pittman followed up Dr. Pearson by providing a report on an updated DUR analysis project on Makena. The DUR project highlighted the impact of the Clinician Administered Drugs and Implantable Drug System Devices (CADD) List on Makena prescribing for Medicaid beneficiaries. A robust discussion occurred regarding additional efforts that could increase the utilization of Makena in beneficiaries with at risk pregnancies. Dr. Fitts asked if there was a "fast-track" approval process in Medicaid for mothers identified by providers as high risk of preterm birth to prevent delays in receiving Makena. Dr. Bloodworth suggested DOM/MS-DUR target providers and beneficiaries in those counties with preterm birth rates higher than the state average for education. The Board also encouraged DOM to explore the potential to partner with primary care physicians, local pharmacies, and home health agencies to administer Makena to beneficiaries in rural areas where access to providers may be limited.

MS-DUR presented the following recommendations:

1. Results should be shared with other health service office directors within Mississippi Medicaid who are currently working to improve access to Makena and an active task force should be developed to address barriers. The results of this analysis should be presented to the MS State Department of Health's Infant Mortality Committee, external agencies, professional associations and healthcare organizations by DOM / MS-DUR.

2. MS-DUR should continue assisting in educating providers and beneficiaries about

Makena. The ordering process can be confusing, particularly for those providers who may not routinely prescribe this medication. Provider education should highlight the ordering process and stress the need for patient education.

3. Providing data issues can be correlated, MS-DUR will work with DOM to assess health outcomes associated with beneficiaries who have received Makena. Specifically, beneficiary gestational weeks at delivery will be compared for pregnancy(s) prior to and after Makena use. Healthcare costs associated with each pregnancy will also be compared.

4. CCOs were invited to present at the next DUR meeting their case management services for Mississippi Medicaid beneficiaries identified as high risk for preterm birth.

Dr. Bloodworth made a motion, seconded by Mr. Smith, to accept the MS-DUR recommendations. The motion was unanimously approved by the Board.

Update on CGRP Inhibitor Prescribing in Mississippi Medicaid

Dr. Pittman presented an analysis on the utilization of CGRP inhibitors in Medicaid since their introduction in May 2018. The majority of claims in Medicaid have occurred since December 2018. The board engaged in healthy discussion of CGRP inhibitor utilization.

MS-DUR presented the following recommendation:

1. MS-DUR will work with the DOM to assess outcomes associated with CGRP inhibitors. MS-DUR will specifically compare change in hospitalizations, ED visits, and utilization of rescue agents for beneficiaries diagnosed with both episodic and chronic migraine receiving CGRP inhibitors.

Ms. Dunaway made a motion, seconded by Dr. Bloodworth, to accept the MS-DUR recommendations. The motion was unanimously approved by the Board.

Concurrent Prescribing of Opioids and Antipsychotics

Dr. Pittman presented the Board with a report on the concurrent prescribing of opioids and antipsychotics. Part of the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act contains Medicaid provisions that pertain to drug review and utilization. One requirement within the Medicaid provisions is for state Medicaid programs to have an automated claims review process to monitor concurrent prescribing of opioids and antipsychotics. The Board held a vigorous discussion regarding options for reviewing concurrent use of opioid and antipsychotics. The consensus from the Board was for DOM to implement a retrospective DUR intervention initially targeting chronic concurrent users of opioids and antipsychotics.

MS-DUR presented the following recommendations:

1. MS-DUR should work with the DOM to develop an automatic claims review process to monitor concomitant use of opioids and antipsychotics and implement the process prior to October 1, 2019.

2. MS-DUR should implement an educational initiative to notify providers and/or pharmacists, depending on the review process being initiated.

Dr. Bloodworth made a motion, seconded by Dr. Fitts, to accept the MS-DUR recommendations. The motion was unanimously approved by the Board.

FDA Drug Safety Updates:
Dr. Pittman presented FDA drug safety communications for March 2019 – April 2019. The Board discussed the safety update related to the sudden discontinuation of opioid pain medicines and the required label changes to guide prescribers on gradual, individualized tapering. The Board expressed a need for providers to have access to tools to calculate morphine equivalent daily doses and conversion factors between formulations. Dr. Taylor referred to a tapering tool that he helped to develop with the Atom Alliance. The Board recommended DOM provide education through a link or reference to a tapering tool for prescribers.

Pharmacy Program Update:
Dr. Noble took this opportunity to update the Board on the opioid edits that will be implemented August 2019. She provided a brief description of the edits that are based on recommendations made by the DUR Board.

Dr. Noble discussed the FDA indication of Vyvanse for binge eating disorder in adults. Presently the only stimulant with FDA approval for binge eating disorder is Vyvanse. No other stimulants have compendia support for binge eating disorder at this time. The recommendation was to add the ICD-10 codes for binge eating disorder to the list of approved diagnoses for stimulants when there is FDA approved indication or compendia support. The Board expressed no objections to the recommendation to add binge eating disorder as one of the approved diagnoses for stimulants.

Dr. Noble also informed the Board that on July 1, 2019, the prescription drug limit for Medicaid beneficiaries will be expanded to 6 prescriptions monthly. She noted that some of the CCOs have already been allowing beneficiaries to receive 6 prescriptions monthly.

Dr. Noble took this opportunity to recognize the Board members whose terms of service on the Board have been completed. She thanked Juanice Glaze, Alice Messer, and James Taylor for their service and dedication to the DUR Board. James Taylor has agreed to serve another term on the DUR Board.

Next Meeting Information:
Dr. Taylor announced that the next meeting of the DUR Board will take place on September 19, 2019 at 1pm.

The meeting adjourned at 2:59 pm.

Submitted,

Eric Pittman, PharmD
Evidence-Based DUR Initiative, MS-DUR

Meeting Location: Woolfolk Building, 501 North West Street, Conference Room 145, Jackson, MS 39201

Contact Information: Pharmacy Bureau:
Chris Yount, 601-359-5253: Christopher.yount@medicaid.ms.gov, or
Jessica Tyson, 601-359-5253; Jessica.Tyson@medicaid.ms.gov

Notice details:

State Agency: MS Division of Medicaid

Public Body: Drug Utilization Board (DUR) Meeting

Subject: Quarterly Meeting

Date and Time: May 23, 2019 at 1PM

Description: The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.